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Abstract
Biomarkers are increasingly used for diagnosis and treatment of transplant related complications 
including the first biomarker-driven interventional trials of acute graft-versus-host disease 
(GvHD). In contrast, the development of biomarkers of chronic GvHD (cGvHD) has lagged due to 
a broader variety of manifestations, overlap with acute GvHD, a greater variability in time to onset 
and maximum severity, and lack of sufficient patient numbers within prospective trials. An 
international workshop organized by a North-American and European consortium was held in 
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Marseille in March 2017 with the goal of identifying strategies for future biomarker development 
to guide cGvHD therapy. As a result of this meeting, two areas were prioritized: the development 
of prognostic biomarkers predicting the subsequent onset of moderate/severe cGvHD, and in 
parallel, the development of qualified clinical grade assays for biomarker quantification. The most 
promising prognostic serum biomarkera are CXCL 9, ST2, matrix metalloproteinase-3, 
osteopontin, CXCL 10, CXCL 11 and CD163. Urine-proteomics and cellular subsets (CD4+ T cell 
subsets, co21low B cells) represent additional potential prognostic biomarkers of cGvHD. A joint 
effort is required to verify the results of numerous exploratory trials before any of the potential 
candidates is ready for validation and subsequent clinical application.
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Introduction
Biomarkers are increasingly considered in the treatment of malignant diseases and are 
currently being validated with regards to outcome prediction in patients with acute graft-
versus-host disease (aGvHD).1, 2 The first trials have been launched where biomarker 
assessment determines aGvHD immunosuppressive interventions through the Blood and 
Marrow Transplant Clinical Trials Network (BMTCTN protocol 1501).2 Despite the 
increasing importance of chronic GvHD (cGvHD)3, the identification of biomarkers in 
cGvHD has lagged due to several factors. These factors include a) a broad variety of 
manifestations which drive prognosis and reflect a potentially heterogeneous 
pathophysiology including overlap with aGvHD, b) a much longer time frame trajectory, and 
c) a lack of sufficient patient numbers within multicenter trials to adjust for the 
heterogeneity of patients with cGvHD. The NIH consensus on cGvHD in 2005 provided the 
basis for dragnustic criteria and biomarker development.4, 5 These consensus 
recommendations were updated in 20146, 7 defining the steps for exploration (identification 
of potential biomarker candidates) and verification of potential biomarkers (replication in 
independent cohorts including test practicability and stability) prior to qualification for 
clinical application. Currently, the development of biomarkers has not passed the verification 
phase mainly due to three reasons. First, the evaluated biomarkers differed in trials due to 
technical reasons and selection of different probes and time points (before or after start of 
immunosuppression) making it currently impossible to select an optimal biomarker panel to 
be validated. Second, cGvHD biomarker studies try to predict development of any cGvHD 
without recognizing subgroups that may have different pathogenesis. Third, heterogeneity in 
the laboratory assays not approved for clinical use could be causing significant variation of 
results in verification trials. For example, CXCL 9 has been identified within several 
cohorts8, 9 as the most sensitive marker while within other cohorts, CXCL 10 performed 
better compared to CXCL 9.10, 11 An additional issue relates to the need for prospective 
documentation of cGvHD at the time of clinical assessment within verification trials. This is 
important, since any retrospective documentation bears the risk of insufficient clinical details 
or possible retrospective bias in severity interpretation with the knowledge of prolonged 
follow up after the sample was obtained. In summary, currently some serum/plasma 
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biomarkers9, 10 and to a lesser extent cellular subpopulations12 represent the most promising 
markers. Urine proteomics may be a potential option13 while gene expression assays require 
further exploration. Besides HLA-typing, none of the genetic markers reached an association 
level sufficient to be useful as a biomarker of cGvHD in a clinical setting.14
To improve the current situation an international workshop on the development of 
biomarkers was organized by a North-American and European consortium which was held 
in Marseille on March 24th and 25th 2017. The workshop included a critical review of 
current evidence and sought to develop strategies for future joint efforts towards qualified 
biomarker development for guidance of cGvHD therapy. The workshop summary is 
presented here.
Consideration of clinical heterogeneity
Development of biomarkers in cGvHD may require some specific consideration with regard 
to the sensitivity and specificity in subgroups with different clinical characteristics. Any 
biomarker should be carefully evaluated during the verification phase with regard to 
cofactors that may affect biomarker levels. These factors for instance can include donor 
source, intensity of the preparative regimen or the use of total body irradiation.6, 10 The 
inclusion of control patients after autologous peripheral stem cell transplantation may help 
to adjust for non-cGvHD confounding factors. Moreover, detection and impact of specific 
organ patterns of cGvHD should be evaluated. An additional issue is understanding the 
contribution of concurrent acute GvHD (called overlap-subtype of cGvHD) which may 
result in misattribution of late acute GvHD biomarkers to cGvHD. Additional crucial issues 
are the impact of immunosuppression and concurrent infections on biomarker levels, as for 
instance steroids suppress sBAFF15 while viral infections with herpes class viruses like 
CMV may induce CXCL 10 expression.16
Development of a clinical grade assay and pre-requisites of validation trials
An additional general issue is that none of the currently applied assays is approved for 
clinical use so qualification of a biomarker requires in parallel a verified diagnostic tool as 
outlined in the 2014 NIH consensus on cGvHD6. As a result, the impact of numerous 
covariates summarized in6 and confirmed in10 require standardized documentation within 
future biomarkers-trials including time after transplantation, stem cell source, immune 
reconstitution, prior acute GvHD, intensity of immunosuppression at time of assessment and 
before assessment, and the presence of infections. Sampling of biomarker probes requires 
application of standard operating procedures (SOPs) focused on the collection, 
transportation, and processing of samples. Biomarker terminology also needs to be 
standardized. To harmonize with concepts used by the US Food and Drug Administration 
(FDA)17 the following terminology was proposed in the context of cGvHD: prognostic 
biomarkers aim to provide information about the risk for subsequent cGvHD while 
predictive biomarkers are applied to predict the course of cGvHD at diagnosis or at later 
timepoints. Diagnostic biomarkers are used to confirm the diagnosis of cGvHD.6
With regard to qualification of biomarker for clinical application two components are to be 
considered: 1) assay qualification (which may be performed on a retrospective cohort) and 
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2) clinical qualification in prospective cohorts and assessment in utility trials. As already 
mentioned standardized assays with standardized SOPs must be verified as well to allow for 
reproducibility in the qualification studies. To address clinical qualification, the workshop 
participants agreed on the need for a prospective multicenter cohort including prospective 
documentation of clinical data (outlined in detail in6). as well as standardized sampling in 
newly diagnosed, untreated patients. Potential markers to be evaluated are outlined below.
Identification of prognostic biomarkers
Prognostic biomarkers predict the future development of cGvHD. The group felt that it is 
most important to prognose the development of moderate-severe forms of cGvHD to target 
for prevention, since mild cGvHD does not cause morbidity and mortality and is associated 
with superior overall survival due to a graft-versus-tumor effect and prevention of mild 
cGvHD could paradoxically worsen outcomes.18, 19 Therefore, any prognostic biomarker 
should have a high negative predictive value to avoid inappropriate prolonged 
immunosuppression, while impaired positive predictive value is less problematic because at 
worst a patient would start treatment of cGvHD once symptoms appear which is currently 
standard management. Potential serum candidates are CXCL 920, ST2, matrix 
metalloproteinase-3, osteopontin9, CXCL 10, CXCL 11,20, 21 and CD163 (plasma).22 Urine 
proteomics may be an additional prognostic approach since it showed a sensitivity and 
specificity of 84% and 78% respectively within 2 separate European cohorts but failed to 
correlate with current cGvHD in an US cohort (Lee, S.J. verbal communication). With 
regard to cellular markers the expansion of naYve CD4+ T cells as well as CD21 low B cells 
may serve as prognostic biomarkers of subsequent cGvHD taking into account that CD21 
low
 B cells consist of at least 3 different subpopulations and it is currently unclear which of 
these is most relevant12, 21, 23 Additional cellular subsets including regulatory T cells, 
regulatory NK cells, and NKT cells are currently being explored but require further 
evaluation.24, 25, With regard to genetic biomarkers, a number of candidates of prognostic 
polymorphisms were identified in small and medium sized cohorts but failed to be 
consistently replicable in larger cohorts underlining the crucial role of sufficiently powered 
replications sets including different donor types and graft sources.14 A summary of trials 
evaluating prognostic, diagnostic and predictive markers is shown in table 1.
Identification of diagnostic biomarkers
While cGvHD is usually easily diagnosed based on clinical and histological criteria7, 26, 27 
certain clinical conditions may benefit from biomarker measurements. For example, a 
considerable portion of patients may be thought to have cGvHD but do not show diagnostic 
signs 7 and require histopathological confirmation which may be invasive (liver, lung)26, 28, 
or difficult to obtain and interpret (eye) or be time consuming.29 In addition, some pediatric 
evaluations are particularly challenged when testing cannot be performed (i.e., pulmonary 
functions testing and Schirmer’s test) and histopathology requires general anesthesia. 
Therefore, an easy to assess biomarker would be a significant advantage in clinical care by 
speeding up the diagnostic evaluation, providing additional certainty of the diagnosis and 
may furthermore serve a quality control purpose for inclusion in clinical trials. Last but not 
least, organ specific biomarkers may help to differentiate active organ involvement caused 
by GvHD from other organ impairments caused by comorbidities like preexisting chronic 
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obstructive pulmonary disease. A number of serum/plasma candidate proteins have been 
explored as diagnostic biomarkers of cGVHD. CXCL 9, CXCL 10, and sBAFF have been 
most frequently associated with the onset of cGvHO,8–10, 30, 31 with anti-LG3, ST2, matrix 
metalloproteinase 3, and osteopontin being additional candidates.9, 10 With regard to 
cellular biomarkers a high proportion of co19+co21low B cells and CD4+CD45RA+CD31+ T 
cells have been associated with diagnosis of cGvHD12, 32 while within a different cohort the 
lack of CXCR3+ (ligand for CXCL 9 &10) CD56bright NK cells correlates with diagnosis of 
cGvHD with CXCR3+CO4+ T cells being an additional cellular marker of interest10 while 
other cellular subsets like regulatory T cells and their ratio to effector T cells require further 
evaluation.24 With regard to organ specific biomarkers very high sBAFF levels and 
expansion of co21low B cells have been associated with lung manifestations.32 In acute 
GvHD, elafin is a specific marker for skin involvement33, 34 and Reg3alpha indicates 
gastrointestinal manifestations and could indicate overlap cGvHD.35 Currently, organ 
specific serum marker for oral or ocular GvHD are lacking but saliva36 or tear proteomics37 
have been explored.
Identification of predictive biomarkers
Limited data are restricted to exploratory studies showing that normalization of sBAFF and 
regeneration of naïve B cells after exposure to rituximab are associated with response to B 
cell depletion38, 39 and ECP.40 Moreover, persisting CXCL 10, CXCL9 and ST2 has been 
associated with active cGvHD although additional studies are needed.30 An additional aspect 
of predictive biomarkers is the differentiation of non-reversible inactive lesions of cGvHD 
from active disease which may be relevant during the course of disease.
Additional biomarkers have been evaluated in different indications recently summarized in6 
and further insight in the pathophysiology of cGvHD was recently summarized in24.
Future collaboration
The first level of qualification requires development and application of qualified assays to 
guarantee that measurement of biomarkers is consistent between laboratories. In parallel, the 
development of certified assays in cooperation with industrial partners for clinical 
application is of crucial relevance, since none of the currently applied methods has been 
certified for clinical application which is the pre-requisite for qualification within clinical 
trials. Since it is unlikely, that a single biomarker will be sufficient to cover all aspects of 
cGvHD, it will be important to define a panel of biomarkers before developing clinical grade 
assays as multiplex ELISA’s are technical challenging and the development of assays using 
direct detection of proteins or protein fragments require a pre-defined panel to be cost 
effective. While assay qualification may be based on already existing samples clinical 
qualification requires a prospective sampling.
First steps will be the implementation of prospective biomarker trials within the US cGvHD-
consortium, the Canadian pediatric ABLE-consortium and the German-Austrian-Swiss 
GvHD consortium including standardized sample preparation, and storage, exchange of 
reference samples and protocols between the centers to test comparability of results followed 
by a prospective cohort study, with internal standards and multiple measures conducted in all 
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participating laboratories. The verification and validation of candidate biomarkers in 
pediatric populations is highly relevant since this is a notoriously underrepresented 
population within clinical trials and adult data may not be extrapolated to the pediatric 
population. In summary a joint effort is required to verify the results of numerous 
exploratory trials before any of the potential candidates is ready for validation and 
subsequent clinical application.
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